DCN and breast carcinoma: Elevated plasma levels of decorin were found to be an independent predictive factor for advanced breast cancer [258], while plasma glypican‐4 levels predicted 2‐year survival in metastatic breast cancer patients with an optimal cut‐off of 4.8 ng/mL [259].